Tennessee is currently home to 1915 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dopaminergic Dysfunction in Late-Life Depression
NCT04469959
Recruiting
Late-Life Depression (LLD), or depression in older adults, often presents with motivational deficits, deficits in performance in cognitive domains including processing speed and executive dysfunction, and mobility impairments. This triad of findings implicate dopaminergic dysfunction as a core pathophysiologic feature in depression, and may contribute to cognitive decline and motor disability. Normal aging results in brain-wide dopamine declines, decreased D1/D2 receptor density, and loss of dop... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/24/2024
Locations: Vanderbilt Psychiatric Hospital, Nashville, Tennessee
Conditions: Late Life Depression, Cognitive Decline, Depressive Disorder, Treatment-Resistant, Levodopa, Gait Impairment
Register for Updates
The Aim of This Study is to Determine if Oocyte Sorting for Group Culture Using an Artificial Intelligence Image Analysis Tool (MagentaTM) Increases the Usable Blastocyst Yield and Subsequent Pregnancy in Patients Undergoing IVF
NCT06521372
Recruiting
The aim of this study is to determine if oocyte sorting for group culture using an artificial intelligence image analysis tool (MagentaTM) increases the usable blastocyst yield and subsequent pregnancy in patients undergoing IVF.
Gender:
ALL
Ages:
All
Trial Updated:
07/23/2024
Locations: Ovation Fertility - Nashville, Nashville, Tennessee
Conditions: Infertility Primary
Register for Updates
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT03990896
Recruiting
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2024
Locations: Vanderbilt University, Nashville, Tennessee
Conditions: Breast Cancer
Register for Updates
Pain With Differing Insufflation Pressures During Laparoscopic Hysterectomy
NCT06508814
Recruiting
The purpose of this study is to determine the effect of decreased insufflation pressure on postoperative pain, analgesic use, and surgical safety and feasibility for laparoscopic hysterectomy.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/19/2024
Locations: University of Tennessee Health Science Center, Memphis, Tennessee
Conditions: Post Operative Pain
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: Vanderbilt University School of Medicine, Nashville, Tennessee
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868
Recruiting
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/17/2024
Locations: Sarah Cannon Cancer Center, Nashville, Tennessee
Conditions: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)
Register for Updates
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
NCT03865589
Recruiting
To perform an receiver operating characteristic (ROC) analysis, define a threshold and quantify the sensitivity and specificity of US SWE for risk stratification of patients into three categories as defined by the European Bone Marrow Transplant (EBMT) adult and pediatric criteria: no sinusoidal obstruction syndrome (SOS), mild to moderate SOS, and severe to very severe SOS. Secondarily, the investigators would also like to quantify the temporal relationship between US SWE changes and SOS diagno... Read More
Gender:
ALL
Ages:
Between 1 month and 99 years
Trial Updated:
07/16/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Stem Cell Transplant Complications
Register for Updates
Improving Surgical Outcomes With Early PT After ACDF
NCT06202443
Recruiting
The goal of this two-group randomized clinical trial is to examine the effects of early postoperative PT compared to delayed postoperative PT for improving outcomes after hospital discharge for ACDF surgery. The main question this clinical trial aims to answer are: * Whether early PT participants will demonstrate greater improvements in outcomes compared to delayed PT participants. * Whether improvements in handgrip strength, cervical endurance, and cervical range of motion will be associated... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Cervical Spine Degeneration, ACDF Surgery
Register for Updates
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
NCT05361720
Recruiting
This phase II trial tests whether using genetic testing of tumor tissue to select the optimal treatment regimen works in treating patients with clear cell renal cell (kidney) cancer that has spread to other places in the body (advanced or metastatic). The current Food and Drug Administration (FDA)-approved regimens for advanced kidney cancer fall into two categories. One treatment combination includes two immunotherapy drugs (nivolumab plus ipilimumab), which are delivered by separate intravenou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
NCT05271292
Recruiting
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: Sarah Cannon Research Center, Nashville, Tennessee
Conditions: Advanced Solid Malignant Tumor, Small Cell Lung Cancer
Register for Updates
Pharmacogenetic Determinants Of Treatment Response In Children
NCT00730678
Recruiting
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates. To investigate the nature of heritability and the genetic basis of pharmacogenetic traits by studying family members of individuals with specific genotypes.
Gender:
ALL
Ages:
All
Trial Updated:
07/10/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: All Malignancies, Children Being Treated for Catastrophic Illness
Register for Updates
Tennessee Alzheimer's Project
NCT05372172
Recruiting
The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals, biosamples, clinical data, and neuroimaging data. The VADRC Clinical Core will create an infrastructure to support research efforts of both local and national investigator studies to develop early detection, prevention, and treatment strategies for Alzheimer's disease. The... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/09/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Aging, Alzheimer Disease, Biomarker, Cognitive Dysfunction, Mild Cognitive Impairment, Dementia, Cognition
Register for Updates